TRESIBA DIN 02467887
Health Canada record
| Active ingredient(s) | INSULIN DEGLUDEC 200 UNIT |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | A10AE06 INSULIN DEGLUDEC |
| Original market date | 15-Sep-2017 |
| Current status date | 15-Sep-2017 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novo Nordisk Canada Inc — licence 100175, currently licensed, last inspection rating C (2023-02-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing INSULIN DEGLUDEC
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02467860 | TRESIBA | NOVO NORDISK CANADA INC | Solution | INSULIN DEGLUDEC 100 UNIT | Marketed |
| 02467879 | TRESIBA | NOVO NORDISK CANADA INC | Solution | INSULIN DEGLUDEC 100 UNIT | Marketed |
| 02474875 | XULTOPHY | NOVO NORDISK CANADA INC | Solution | INSULIN DEGLUDEC 100 UNIT; LIRAGLUTIDE 3.6 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 19717 | 2017-08-25 | New Drug Submission (NDS) |
International API supply for INSULIN DEGLUDEC
4 active FDA Drug Master Files.
Request a quote for TRESIBA